Clinical trial
A Multicenter Study of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as First-line Therapy in Patients (Pts) With Metastatic Pancreatic Cancer: PAAG.
Name
2022-351-02
Description
It is a trial to assess the efficacy and safety of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as first-line Therapy in Patients (Pts) With Metastatic Pancreatic Cancer.
Trial arms
Trial start
2022-07-21
Estimated PCD
2024-05-01
Trial end
2024-05-01
Status
Completed
Phase
Early phase I
Treatment
Penpulimab
Penpulimab 200 mg administered intravenously every 3 weeks.
Arms:
Penpulimab+Anlotinib+Nab-paclitaxel+Gemcitabine
Other names:
AK105
Anlotinib
12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
Arms:
Penpulimab+Anlotinib+Nab-paclitaxel+Gemcitabine
Nab paclitaxel
125mg/m\^2,administered intravenously on days 1 and 8 of every 21-day cycle.
Arms:
Penpulimab+Anlotinib+Nab-paclitaxel+Gemcitabine
Gemcitabine
1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle.
Arms:
Penpulimab+Anlotinib+Nab-paclitaxel+Gemcitabine
Size
66
Primary endpoint
Objective Response Rate (ORR)
up to 3 years
Disease Control Rate (DCR)
up to 3 years
Eligibility criteria
Inclusion Criteria:
* Ages ≥18 years,ECOG ≤ 2,Estimated survival time \> 3 months
* Histologically or Cytologically confirmed metastatic pancreatic adenocarcinoma
* Based on Response Evaluation Criteria In Solid Tumors (RECIST1.1), there should be at least one measurable lesion
* Patients have never received systematical anti-cancer therapy
* Laboratory examination meets the following requirements:White blood cell (WBC) ≥3.0×109/L; absolute neutrophil count (ANC) ≥1.5×109/L; Hemoglobin (HB) ≥90g/L; platelet count(PLT) ≥75×109/L; Total bilirubin (TBIL) ≤1.5× normal upper limit (ULN); Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)≤2.5×ULN, if accompanied by liver metastasis, ALT and AST≤5×ULN; Serum creatinine (Cr) ≤1×ULN or creatinine clearance (CCr)≥50ml/min;
* Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) \> 50%
* Patients of childbearing age should take appropriate protective measures before enrollment and during the trial
* Volunteer to join the study, sign the informed consent, have good compliance, and cooperate with follow-up
* Ability to follow the study protocol and follow-up procedures.
Exclusion Criteria:
* Patients have ever received any systematical anti-cancer therapy in the past
* Patients who participated in other clinical trials in the past 4 weeks
* According to the investigator, patients who surgically available or potentially treatable(Patients who voluntarily give up surgical treatment can be enrolled after evaluation by the investigator)
* Patients with moderate ascites requiring drainage
* Patients with CNS metastases and/or carcinomatous meningitis
* Patients with history of other primary malignancies except: 1) complete remission before enrollment for at least 2 years and requiring no additional treatment during the study period; 2) Adequately treated non-melanoma skin cancer or lentiform malignancy with no evidence of disease recurrence; 3) Adequately treated carcinoma in situ with no evidence of disease recurrence;
* Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs
* Patients with bleeding tendency.
* Pregnant or lactating women.
* Drug abuse, clinical or psychological or social factors that impact informed consent or the conduct of the study
* Patients who may be allergic to PD-1 monoclonal antibody, anlotinib, albumin-bound paclitaxel and gemcitabine
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 66, 'type': 'ACTUAL'}}
Updated at
2024-05-09
1 organization
2 products
2 drugs
1 indication
Product
PenpulimabIndication
Pancreatic CancerDrug
AnlotinibProduct
Nab paclitaxelDrug
Gemcitabine